Articles

Videos

Podcasts

Clinical

Results from the LOTIS-2 and LOTIS-3 trials show durable responses and a manageable toxicity profile among patients with both diffuse large B-cell lymphoma and mantle cell lymphoma treated with loncastuximab tesirine-lpyl (Zynlonta). 

Updated Clinical Trial Results Demonstrate Durable Response to Loncastuximab Tesirine-lpyl

The demand for drug treatments in Europe and North American has increased in recent years, as awareness of the bleeding disorder rises.

Treating Hemophilia Depends on Available Types of Clotting Factors

The FDA also approved dabigatran etexilate oral pellets for the prevention of recurrent clots in patients aged 3 months to less than 12 years of age who have completed treatment for their first venous thromboembolism. 

First Oral Medication for Blood Thinning in Children Granted FDA Approval 

Pharmacists can educate patients about a pair of new treatment options for multiple myeloma approved by the FDA in March 2021.

A Closer Look at Recent FDA Approvals for Multiple Myeloma 

The findings led to the FDA accepting the supplemental Biologics License Application and Priority Review designation for treatment, according to a Gilead press release.

Brexucabtagene Autoleucel Demonstrates High Response Rate with Relapsed, Refractory B-cell Acute Lymphoblastic Leukemia

Avapritinib is approved for adult patients with advanced systemic mastocytosis, including individuals with aggressive systemic mastocytosis, systemic mastocytosis with an associated hematological neoplasm, and mast cell leukemia.

FDA Approves Avapritinib for Advanced Systemic Mastocytosis

Updated research offers an additional 2 years of follow-up data and statistics on treatment with a combination of ibrutinib and venetoclax in patients with chronic lymphocytic leukemia.

Study: Combination Targeted Therapy Provides Durable Remission for Patients with Chronic Lymphocytic Leukemia

The addition of daratumumab to lenalidomide and dexamethasone resulted in a significant benefit to overall survival in patients with newly diagnosed multiple myeloma who were ineligible for autologous stem cell transplant and were treated to progression, according to the results of the phase 3 MAIA study.

Daratumumab Demonstrates Benefit to Overall Survival for Certain Patients with Multiple Myeloma

Results from part A of a phase 3 trial showed sutimlimab caused patients to experience a rapid and sustained inhibition of C1-activated hemolysis in patients with cold agglutinin disease. 

Data Reinforce Sutimlimab as First-in-Class Investigational C1s Inhibitor for Hemolysis in Patients With Cold Agglutinin Disease

Teclistamab is an off-the-shelf, T-cell redirecting, bispecific antibody targeting both B-cell maturation antigen (BCMA) and CD3 receptors.

Hematology